Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies

SEOUL - Despite Celltrion's claims that it is shifting away from its contract manufacturing business to focus on biosimilars, the company revealed an ongoing deal with Sanofi-Aventis for clinical materials and process development for monoclonal antibody therapeutics and announced the near completion of its CMO plant